Omega Funds

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Andrew Alliance is a Swiss robotics company that designs and commercializes automated liquid-handling solutions for the life sciences sector. The company offers a suite of hardware and software tools, including OneLab, a graphical interface to design liquid-handling workflows; Andrew+, a pipetting robot compatible with conventional electronic pipettes; Pipette, a cloud-enabled device to improve ergonomics and traceability; and Andrew, a portable liquid-handling robot that can operate unattended with manual pipettes. It also provides Andrew Assistant, a protocol-design software to create, verify, and document biology protocols that require quantitative liquid handling. Products are assembled and tested in Switzerland, with service and support based in Geneva and an office in Boston, and are sold directly and through distributor partners internationally. Founded in 2011, Andrew Alliance is an independent Swiss company that combines robotics, vision and software to enable researchers to perform precise, repeatable liquid-handling operations more efficiently, aiming to enhance accuracy and throughput in laboratory workflows.

Andrew Alliance is a Swiss robotics company that designs and commercializes automated liquid-handling solutions for the life sciences sector. The company offers a suite of hardware and software tools, including OneLab, a graphical interface to design liquid-handling workflows; Andrew+, a pipetting robot compatible with conventional electronic pipettes; Pipette, a cloud-enabled device to improve ergonomics and traceability; and Andrew, a portable liquid-handling robot that can operate unattended with manual pipettes. It also provides Andrew Assistant, a protocol-design software to create, verify, and document biology protocols that require quantitative liquid handling. Products are assembled and tested in Switzerland, with service and support based in Geneva and an office in Boston, and are sold directly and through distributor partners internationally. Founded in 2011, Andrew Alliance is an independent Swiss company that combines robotics, vision and software to enable researchers to perform precise, repeatable liquid-handling operations more efficiently, aiming to enhance accuracy and throughput in laboratory workflows.

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel tetracycline-based therapies to treat infectious diseases and related public health threats. Its lead programs center on omadacycline, a broad-spectrum tetracycline available in oral and intravenous forms for community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, urinary tract infections, and other serious infections, and sarecycline for acne and rosacea. The company emphasizes expertise in advanced tetracycline chemistry to address antibiotic resistance. Paratek collaborates with industry and academic partners, including licenses with Zai Lab and Allergan, a license with Tufts University to develop products for bacterial diseases, and a cooperative R&D agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline. Founded in 1996 and headquartered in Boston, Paratek aims to bring therapies that improve patient outcomes and address public health challenges.